Star Therapeutics raises $200m to restart drug discovery after Vega sale and Electra IPO

Star Therapeutics announced $200 million in new venture funding on Friday 23 October 2026, co-led by OrbiMed and Janus Henderson, and said it will use the money to restart early-stage drug research after selling one subsidiary and floating another ¹. Chief executive Adam Rosenthal described the round as a “reset” and said the company will “go back into stealth mode” ¹.

The round and the exits behind it

RA Capital Management and Sofinnova Investments are among the other investors in the round, alongside the co-leaders ¹. Star has not said how many experimental biologics it will advance, only that they target haematological and immune conditions ¹.

The raise follows two exits in 2026. Incyte bought Vega Therapeutics, which was developing a treatment for Von Willebrand disease, in a deal worth as much as $2 billion ¹. Rosenthal said Vega could have taken the drug to market itself but accepted Incyte's offer because the larger company had “more capabilities and resources clinically and commercially” for a launch ¹. Electra Therapeutics, a second Star spinout working on secondary hemophagocytic lymphohistiocytosis, raised $350 million in an initial public offering priced in September ¹.

Star was founded in 2018 around a group of rare disease assets and, in its early years, resembled hub-and-spoke developers such as Roivant Sciences and PureTech Health ¹. That model is being dropped. Rosenthal said the company has moved away from separately branded offshoots and now wants to be seen simply as Star ¹. Its new target is molecules that are “hard to replicate and copy elsewhere”, rather than drugs built to edge out the current standard of care ¹.

What it means for the market

For investors, the round shows crossover and specialist funds backing a team on its record of exits rather than on a disclosed pipeline. Vish Sridharan, an assistant portfolio manager and research analyst at Janus Henderson, said the firm does “not often invest in companies at this stage of development” and pointed to Star's ability to repeatedly find areas of unmet need ¹. A public markets investor co-leading a private, undisclosed-stage round is an unusual signal of appetite for early biotech risk.

For pharma business development teams, the Vega sale is the relevant precedent. A rare disease asset grown inside a venture-funded platform was sold to a mid-sized pharma company for up to $2 billion, with the seller choosing a partner over an independent launch ¹. Star's shift away from named spinouts also suggests that future assets will be offered from a single company rather than through separately financed subsidiaries ¹.

Caveats

Star has disclosed neither the number of programmes nor their targets or stage, so the size of its new pipeline cannot be judged ¹. The figures for the Vega deal are the maximum value, not the upfront payment ¹. With the company returning to stealth, little further detail is likely in the near term, and Rosenthal has said only that the work will focus on haematological and immune conditions ¹.